Literature DB >> 26723518

Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection.

Paola Cavalcante1, Barbara Galbardi2, Sara Franzi3, Stefania Marcuzzo4, Claudia Barzago5, Silvia Bonanno6, Giorgia Camera7, Lorenzo Maggi8, Dimos Kapetis9, Francesca Andreetta10, Amelia Biasiucci11, Teresio Motta12, Carmelo Giardina13, Carlo Antozzi14, Fulvio Baggi15, Renato Mantegazza16, Pia Bernasconi17.   

Abstract

Considerable data implicate the thymus as the main site of autosensitization to the acetylcholine receptor in myasthenia gravis (MG), a B-cell-mediated autoimmune disease affecting the neuromuscular junction. We recently demonstrated an active Epstein-Barr virus (EBV) infection in the thymus of MG patients, suggesting that EBV might contribute to the onset or maintenance of the autoimmune response within MG thymus, because of its ability to activate and immortalize autoreactive B cells. EBV has been reported to elicit and modulate Toll-like receptor (TLR) 7- and TLR9-mediated innate immune responses, which are known to favor B-cell dysfunction and autoimmunity. Aim of this study was to investigate whether EBV infection is associated with altered expression of TLR7 and TLR9 in MG thymus. By real-time PCR, we found that TLR7 and TLR9 mRNA levels were significantly higher in EBV-positive MG compared to EBV-negative normal thymuses. By confocal microscopy, high expression levels of TLR7 and TLR9 proteins were observed in B cells and plasma cells of MG thymic germinal centers (GCs) and lymphoid infiltrates, where the two receptors co-localized with EBV antigens. An increased frequency of Ki67-positive proliferating B cells was found in MG thymuses, where we also detected proliferating cells expressing TLR7, TLR9 and EBV antigens, thus supporting the idea that EBV-associated TLR7/9 signaling may promote abnormal B-cell activation and proliferation. Along with B cells and plasma cells, thymic epithelium, plasmacytoid dendritic cells and macrophages exhibited enhanced TLR7 and TLR9 expression in MG thymus; TLR7 was also increased in thymic myeloid dendritic cells and its transcriptional levels positively correlated with those of interferon (IFN)-β. We suggested that TLR7/9 signaling may be involved in antiviral type I IFN production and long-term inflammation in EBV-infected MG thymuses. Our overall findings indicate that EBV-driven TLR7- and TLR9-mediated innate immune responses may participate in the intra-thymic pathogenesis of MG.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Epstein–Barr virus; Myasthenia gravis; Thymus; Toll-like receptor 7; Toll-like receptor 9

Mesh:

Substances:

Year:  2015        PMID: 26723518     DOI: 10.1016/j.imbio.2015.12.007

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  20 in total

1.  Systems Pharmacology and Molecular Docking Reveals the Mechanisms of Nux Vomica for the Prevention of Myasthenia Gravis.

Authors:  Chao Qiu; Qiang Chen; Qun Hou; Guanshu Qi
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-26       Impact factor: 2.650

Review 2.  Myasthenia gravis and infectious disease.

Authors:  Nils Erik Gilhus; Fredrik Romi; Yu Hong; Geir Olve Skeie
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849

Review 3.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

4.  Reduced plasmablast frequency is associated with seronegative myasthenia gravis.

Authors:  Jeffrey T Guptill; Richard Barfield; Cliburn Chan; Melissa A Russo; Doug Emmett; Shruti Raja; Janice M Massey; Vern C Juel; Lisa D Hobson-Webb; Karissa L Gable; Natalia Gonzalez; Alex Hammett; James F Howard; Manisha Chopra; Henry J Kaminski; Zaeem A Siddiqi; Mattingly Migdal; John S Yi
Journal:  Muscle Nerve       Date:  2020-12-24       Impact factor: 3.217

5.  Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?

Authors:  Paola Cavalcante; Stefania Marcuzzo; Sara Franzi; Barbara Galbardi; Lorenzo Maggi; Teresio Motta; Raffaella Ghislandi; Antonella Buzzi; Luisella Spinelli; Lorenzo Novellino; Fulvio Baggi; Carlo Antozzi; Fabio Conforti; Tommaso Martino De Pas; Massimo Barberis; Pia Bernasconi; Renato Mantegazza
Journal:  Oncotarget       Date:  2017-09-08

Review 6.  Autoimmune Thyroiditis and Myasthenia Gravis.

Authors:  Angela Lopomo; Sonia Berrih-Aknin
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-13       Impact factor: 5.555

Review 7.  Synergistic Activation of Toll-Like and NOD Receptors by Complementary Antigens as Facilitators of Autoimmune Disease: Review, Model and Novel Predictions.

Authors:  Robert Root-Bernstein
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

8.  ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats.

Authors:  Oliver A Garden; Linda Kidd; Angela M Mexas; Yu-Mei Chang; Unity Jeffery; Shauna L Blois; Jonathan E Fogle; Amy L MacNeill; George Lubas; Adam Birkenheuer; Simona Buoncompagni; Julien R S Dandrieux; Antonio Di Loria; Claire L Fellman; Barbara Glanemann; Robert Goggs; Jennifer L Granick; Dana N LeVine; Claire R Sharp; Saralyn Smith-Carr; James W Swann; Balazs Szladovits
Journal:  J Vet Intern Med       Date:  2019-02-26       Impact factor: 3.333

9.  Autoimmune/inflammatory syndrome induced by adjuvants-ASIA-related to biomaterials: analysis of 45 cases and comprehensive review of the literature.

Authors:  Jaume Alijotas-Reig; Enrique Esteve-Valverde; Natalia Gil-Aliberas; Victor Garcia-Gimenez
Journal:  Immunol Res       Date:  2018-02       Impact factor: 4.505

10.  Use of Toll-Like Receptor Agonists to Induce Ectopic Lymphoid Structures in Myasthenia Gravis Mouse Models.

Authors:  Marieke Robinet; Bérengère Villeret; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Front Immunol       Date:  2017-08-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.